Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.

Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with ...

A Delaware federal judge on Monday rejected requests from Pfizer (PFE), BioNTech (BNTX), and Moderna (MRNA) to dismiss ...

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 ...

Moderna’s share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from ...

A federal judge in Delaware on Monday rejected Pfizer , BioNTech and Moderna's requests to dismiss ​patent lawsuits filed ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

Sanofi (Nasdaq: SNY) deprioritized its mRNA flu shot effort. But it is still vigorously defending its substantial share of the flu vaccine market, with its egg-grown Fluzone products and egg-free ...

That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of ...

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be. That approach just cleared its ...

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, ...